N-(indane-1-yl)methanesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-(indane-1-yl)methanesulfonamide
• 英文别名: N-methylsulfonyl-1-aminoindan；N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide
• 化学式: C₁₀H₁₃NO₂S
• mdl: MFCD09991847
• 分子量: 211.285
• InChiKey: JYFDMPBRLUCSLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,3-二氢-1H-茚-1-醇 在 叠氮磷酸二苯酯 、 palladium on activated charcoal 、 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 为溶剂， 反应 52.0h， 生成 N-(indane-1-yl)methanesulfonamide
  参考文献：
  名称：

  Carbonic anhydrase inhibitory properties of novel sulfonamide derivatives of aminoindanes and aminotetralins

  摘要：

  Six sulfonamides derived from indanes and tetralines were synthesized. The human carbonic anhydrase isozymes hCA I and hCA II inhibition effects of the synthesized sulfonamides were determined. From these compounds, while N-(5,6-dimethoxy-2,3-dihydro-1H-inden-2-yl) methane sulfonamide showed the most potent inhibitory effect against hCA I (K-i = 46 +/- 5.4 mu M, r(2) = 0.978), N-(1,2,3,4-tetrahydronaphthalene-2-yl) methanesulfonamide was found to have the best inhibitory effect against hCA II (K-i = 94 +/- 7.6 mu M, r(2) = 0.982).

  DOI：

  10.3109/14756366.2012.750311

文献信息

• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。
• Amidation of Saturated C−H Bonds Catalyzed by Electron-Deficient Ruthenium and Manganese Porphyrins. A Highly Catalytic Nitrogen Atom Transfer Process
  作者：Xiao-Qi Yu、Jie-Sheng Huang、Xiang-Ge Zhou、Chi-Ming Che

  DOI：10.1021/ol000107r

  日期：2000.7.1

  Amidation of a variety of hydrocarbons with PhI=NTs catalyzed by ruthenium and manganese meso-tetrakis(pentafluorophenyl)porphyrins 1 and 2 afforded N-substituted amides in up to 92% yields with good to excellent substrate conversions. By employing catalyst 2, exceptionally high turnovers (up to 2600) were achieved, and the amidations can be effected by directly using PhI(OAc)(2)/NH(2)R as amidating

  钌和锰的内消旋四（五氟苯基）卟啉锰1和2催化的PhI = NTs的各种烃酰胺化反应可得到N-取代的酰胺，收率高达92％，且底物转化率良好。通过使用催化剂2，可以实现极高的周转率（最高2600），并且可以通过直接使用PhI（OAc）（2）/ NH（2）R作为酰胺化试剂来实现酰胺化。在R = COCF（3）的情况下，可以实现高达90％的产率的直接胺化。
• [EN] PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS<br/>[FR] ANALOGUES DE MORPHINANE PYRIDONE-SULFONES UTILISÉS COMME LIGANDS DE RÉCEPTEURS OPIOÏDES
  申请人：PURDUE PHARMA LP

  公开号：WO2015102682A1

  公开（公告）日：2015-07-09

  The application is directed to Pyridone-sulfone morphinan analogs compounds of Formula I: or pharmaceutically acceptable salts and solvates thereof, wherein ==, R1, R2, R3, R4 and Z are as defined as set forth in the specification. The invention is also directed to use of the compounds of Formula I or the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the odulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

  该应用程序针对Formula I的吡啶酮-砜吗啡类似物化合物，或其药学上可接受的盐和溶剂，其中==，R1，R2，R3，R4和Z的定义如规范所述。该发明还涉及使用Formula I的化合物或其药学上可接受的盐和溶剂来治疗对一种或多种阿片受体调节敏感的紊乱，或作为合成中间体。本发明的某些化合物特别适用于治疗疼痛。
• 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：EP3328843A1

  公开（公告）日：2018-06-06